To identify obstacles, solutions, and treatment recommendations for initiating therapy with monoclonal antibodies (mAbs) for Alzheimer’s disease (AD) that have been highlighted in published literature.

Of 505 articles extracted, 26 met selection criteria. Publications described challenges throughout all phases of AD management, including evaluation, diagnosis, treatment, and monitoring. Candidate evaluation was noted to be complicated by variable use of neurocognitive and behavioral assessments and lack of familiarity with treatment eligibility. Several publications emphasized the need to identify patients at risk for adverse events, particularly amyloid-related imaging abnormalities, and to define the role of risk-stratification strategies (eg, genotyping). Resource-related barriers were also highlighted for mAb administration and patient monitoring. Increasing capacity of healthcare systems was recommended to address increased demand for early detection, assessment, and diagnosis of eligible individuals. Additional solutions included infusion administration in diverse care settings and development of monitoring strategies with broader accessibility.